BCL-2: a new therapeutic target in estrogen receptor-positive breast cancer?
Prosurvival protein BCL-2 is overexpressed in estrogen receptor positive (ER(+)) breast cancer. In this issue of Cancer Cell, Vaillant and colleagues demonstrate that targeting BCL-2 with BH3 mimetics improves the response of xenografts from primary ER(+) breast tumors to endocrine therapy and reduces tamoxifen-induced endometrial hyperplasia, a strategy with potential clinical applicability.